Negative in Ames, human lymphocyte chromosomal aberration and rat micronucleus assays
“Mutagenesis Etrasimod was negative in a battery of in vitro (Ames, chromosomal aberration in human peripheral blood lymphocytes) and in vivo (rat micronucleus) assays.”
Hemangioma/hemangiosarcoma at ≥46-fold MRHD exposure; 2-year rat: no carcinogenic potential up to 88–198-fold
“hemangioma/hemangiosarcoma were observed at exposures ≥ 46-fold the exposure at the MRHD (based on AUC comparison). In a two-year carcinogenicity study in rats, no evidence of carcinogenic potential was observed at exposures up to 88- and 198-fold the exposure at the MRHD in males and females, respectively (based on AUC comparison).”
✓ VerifiedFDA multi-discipline review, p. 43Source ↗
Reproductive & developmental
Rat and rabbit EFD: embryolethality and fetal malformations at 5- and 6-fold MRHD exposure
“In animal reproduction studies, administration of etrasimod during organogenesis produced adverse effects on development, including embryolethality and fetal malformations, in both rats and rabbits at maternal exposures 5 and 6 times, respectively, the exposure at the maximum recommended human dose (MRHD).”
No significant effects on hERG current, dog cardiovascular, rat CNS or rat respiratory function
“In a standard battery of nonclinical safety pharmacology studies, etrasimod had no significant effects on hERG channel current in vitro, cardiovascular function in dogs, CNS parameters in rats, or respiratory function in rats.”
✓ VerifiedFDA multi-discipline review, p. 42Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative